1. Home
  2. BGT vs DCTH Comparison

BGT vs DCTH Comparison

Compare BGT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Floating Rate Income Trust

BGT

BlackRock Floating Rate Income Trust

HOLD

Current Price

$11.31

Market Cap

320.3M

Sector

Finance

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.93

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGT
DCTH
Founded
2004
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.3M
350.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BGT
DCTH
Price
$11.31
$9.93
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$22.60
AVG Volume (30 Days)
107.2K
484.9K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
10.77%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$79,603,000.00
Revenue This Year
N/A
$131.69
Revenue Next Year
N/A
$39.22
P/E Ratio
N/A
$288.36
Revenue Growth
N/A
251.54
52 Week Low
$10.89
$8.12
52 Week High
$13.42
$18.23

Technical Indicators

Market Signals
Indicator
BGT
DCTH
Relative Strength Index (RSI) 46.32 50.27
Support Level $11.29 $9.98
Resistance Level $11.43 $10.37
Average True Range (ATR) 0.08 0.35
MACD 0.02 -0.02
Stochastic Oscillator 47.85 24.48

Price Performance

Historical Comparison
BGT
DCTH

About BGT BlackRock Floating Rate Income Trust

Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: